<div id="readability-page-1"><div><p>China Medical System Holdings (SEHK:867) has secured Chinese regulatory approval for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis adult chronic kidney disease patients, expanding its presence in the nephrology segment.</p> <p>See our latest analysis for China Medical System Holdings.</p> <p>The share price is at HK$13.27 after a 1 day share price return of 2.47%. However, the 30 day share price return shows a 14.05% decline, which contrasts with an 82.01% 1 year total shareholder return. This suggests that momentum has cooled recently, even after a strong year.</p> <p>If this kind of product approval has you thinking about where medical technology and AI might intersect next, it could be worth scanning 127 healthcare AI stocks for more ideas.</p> <p>So with a HK$13.27 share price, an intrinsic value estimate showing a roughly 62% discount, and a recent 14.05% 30‑day pullback after an 82.01% 1‑year return, is there a real opportunity here or is the market already pricing in future growth?</p> <h2>Price-to-Earnings of 19x: Is it justified?</h2> <p>On a P/E of 19x at a last close of HK$13.27, China Medical System Holdings screens as more expensive than the Hong Kong pharmaceuticals industry average of 11.5x, even though internal fair value work points to a substantial discount to intrinsic value.</p> <p>The P/E multiple compares the share price to earnings per share, so it effectively shows how much investors are paying for each dollar of profit. For a pharmaceutical group with HK$8,212.06m of revenue and HK$1,488.89m of net income, this lens helps you judge whether the current price lines up with the earnings profile and expectations baked into forecasts.</p> <p>Analyst statements indicate earnings are expected to grow 21.42% per year and revenue 14.8% per year, faster than the broader Hong Kong market. This can help explain why the market is currently willing to pay more than the sector average. At the same time, the estimated fair P/E of 23.7x suggests that if those projections play out, the multiple could move closer to that level, even though return on equity is described as low at 8.2% and net profit margins have compressed from 21.7% to 18.1%.</p> <p>Compared with peers, the picture is mixed. The stock trades on a richer P/E than the Hong Kong pharmaceuticals industry at 11.5x, yet it is described as good value against a peer average multiple of 23.8x and also against the estimated fair P/E of 23.7x. That combination points to a company priced above the industry but below what some comparative models and peer group averages imply could be justified if earnings forecasts are met.</p> <p>Explore the SWS fair ratio for China Medical System Holdings</p> <p><strong>Result: Price-to-Earnings of 19x (UNDERVALUED)</strong></p> <p>However, you still need to weigh risks like a 14.05% 30 day share price decline and compressed net profit margins against any optimism around earnings forecasts.</p> <p>Find out about the key risks to this China Medical System Holdings narrative.</p> <h2>Another View: What Does The SWS DCF Model Say?</h2> <p>While the 19x P/E suggests China Medical System Holdings is cheaper than a fair ratio of 23.7x, the SWS DCF model points to a different anchor, with an estimated future cash flow value of HK$34.88 versus a share price of HK$13.27. That gap is described as a 62% discount, but how comfortable are you relying on long term cash flow assumptions?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out China Medical System Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 242 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>With all this in mind, does the current setup look attractive or stretched to you, and how confident are you in the assumptions behind it? Take a moment to explore what is driving optimism by reviewing the 3 key rewards</p> <h2>Looking for more investment ideas?</h2> <p>If you stop with just one stock, you might miss opportunities that fit your style even better, so treat this as the start of your search, not the end.</p> <ul> <li>Target resilient names by scanning 286 resilient stocks with low risk scores, which aims to keep risk in check while you focus on compounding returns.</li> <li>Hunt for quality at a discount using 242 high quality undervalued stocks, which highlights companies with strong fundamentals trading below their estimated worth.</li> <li>Cast a wider net over under followed opportunities through screener containing 589 high quality undiscovered gems, which spotlights businesses many investors may be overlooking.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

159316

159849

516930

512290

159506

00867

520880

<p>China Medical System Holdings (SEHK:867) has received regulatory approval for Desidustat Tablets, enhancing its nephrology segment. The share price is HK$13.27, reflecting a 2.47% increase over one day but a 14.05% decline over 30 days. Despite a strong 82.01% return over the past year, the stock trades at a P/E of 19x, higher than the industry average of 11.5x. Analysts project earnings growth of 21.42% annually. The SWS DCF model estimates a fair value of HK$34.88, indicating a 62% discount at the current price, suggesting potential undervaluation despite risks.</p>

Simplywall

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Medical System Holdings (SEHK:867) Valuation After Desidustat Approval And Recent Share Price Pullback